Complement C5a-Mediated TAM-ing of Antitumor Immunity Drives Squamous Carcinogenesis

Cancer Cell. 2018 Oct 8;34(4):531-533. doi: 10.1016/j.ccell.2018.09.005.


In this issue of Cancer Cell, Medler et al. demonstrate that fibrinolytic enzyme-mediated generation of complement C5a reprograms tumor-infiltrating C5aR1+ macrophages into an immunosuppressive phenotype that dampens CD8+ T cell responses during squamous carcinogenesis. C5aR1 blockade combined with chemotherapy offers a promising immunomodulatory strategy for treating squamous cell carcinoma.

Publication types

  • Comment

MeSH terms

  • Carcinogenesis
  • Carcinoma, Squamous Cell*
  • Complement C5a*
  • Humans
  • Receptor, Anaphylatoxin C5a
  • T-Lymphocytes


  • Receptor, Anaphylatoxin C5a
  • Complement C5a